Clinical Trials Logo

Inositol clinical trials

View clinical trials related to Inositol.

Filter by:
  • None
  • Page 1

NCT ID: NCT05448378 Completed - Insulin Clinical Trials

Evaluation of D-chiro-inositol Treatments

Start date: June 4, 2022
Phase: N/A
Study type: Interventional

Healthy women will take tablets containing 600 mg D-chiro-inositol twice per day for one month. We will evaluate metabolic and hormonal.parameters, as insulienmia, glycemia, estradiol, testosterone.

NCT ID: NCT05448365 Recruiting - Uterine Fibroids Clinical Trials

Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid

Start date: July 1, 2022
Phase: Phase 3
Study type: Interventional

The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6. The patients will be evaluated at baseline and after three months of treatment with placebo or product.

NCT ID: NCT04306692 Terminated - Clinical trials for Polycystic Ovary Syndrome

Myo-inositol Versus Clomiphene Citrate in PCOS

Start date: July 2, 2020
Phase: Phase 4
Study type: Interventional

Specific aim: To compare inositol and the golden standard first line treatment of ovulation induction, namely clomiphene citrate.

NCT ID: NCT03283813 Recruiting - Insulin Resistance Clinical Trials

ZIMBA: Clinical Trial in Paediatric Obesity

ZIMBA
Start date: February 5, 2018
Phase: Phase 4
Study type: Interventional

Myoinositol (MI) and D-chiro inositol (DCI) are isomeric forms of inositol that were found to have insulin-like properties, acting as second messengers in the insulin intracellular pathway; both of these molecules are involved in the increasing insulin sensitivity of different tissues to improve metabolic and ovulatory functions. Myoinositol is the predominant form that can be found in nature and food. Inositol has been mainly used as a supplement in treating several pathologies such as polycystic ovary syndrome (PCOS), metabolic syndrome, type 2 diabetes mellitus (T2DM) and gestational diabetes (GDM). In the case of GDM, a condition defined as a glucose impairment first detected in pregnancy, a preventive role of inositol for GDM onset was recognized. In addition, inositol has been studied as a therapeutic option for the treatment of GDM and T2DM. The main effect of inositol is decreasing the level of insulin resistance. Consequently, a potential role of inositol as a treatment option could be hypothesized for other conditions typically characterized by insulin resistance like metabolic syndrome and obesity. Zinc also plays an important role in insulin action and carbohydrate metabolism. It may also have a protective role in the prevention of atherogenesis. Several human studies have demonstrated that Zinc supplementation reduces total cholesterol, LDL cholesterol and triglycerides, in addition to increasing the HDL cholesterol levels. Studies have shown that diabetes is accompanied by hypozincemia and high levels of Zinc in urine. In addition Zinc is also an integral part of key anti-oxidant enzymes and Zinc deficiency impairs their synthesis, resulting in increased oxidative stress. A supplementation with Myo-Inositol and Zinc could represent a valid strategy in paediatric obesity in addiction to a standard approach. The purpose of our study is to evaluate the supplementation of Myo-inositol and Zinc in the treatment of paediatric obesity.